Morphoceuticals is a TechBio company focused on understanding and manipulating the bioelectrome to induce regeneration and treat disease. With its scientific co-founders Mike Levin and David Kaplan, Morphoceuticals is creating the first atlas of the bioelectrome. The bioelectrome is the set of electrical communication networks within the body that bind multi-cellular collectives together for a common purpose, maintaining tissue and organ level integrity and health. By understanding and manipulating these networks, Morphoceuticals aims to rewrite them for the treatment of conditions that are inadequately addressed by existing therapeutic strategies.
MassBio Member Spotlight: Morphoceuticals, Inc.
Location: Medford, MA
Business Type: Therapeutics development
Leadership:
- Jim Jenson, PhD | Chief Executive Officer
- Michael Levin, PhD | Scientific Co-founder
- David Kaplan, PhD | Scientific Co-founder
- Nicolas Palacios-Prado, PhD | Director of Technology Development
- Roger Pomerantz, MD | Chairman, Board of Directors
Website: www.morphoceuticals.com